ReviewAmerican journal of hematology2021
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
Review in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients.Frontiers in immunology · 2026Trial
- Rituximab and corticosteroids for M-protein-negative PGNMID: case report.BMC nephrology · 2026Article
- Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study.British journal of haematology · 2026Article
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance.Journal of the advanced practitioner in oncology · 2026Article
- Clinical predictors of monoclonal gammopathy of renal significance: a multicenter study in Japan.Clinical and experimental nephrology · 2026Article
- Progression of IgM Monoclonal Gammopathy of Renal Significance (MGRS) to Symptomatic Waldenström Macroglobulinemia: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- [Chinese expert consensus on screening and clinical application of monoclonal immunoglobulins(2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.Canadian journal of kidney health and disease · 2025Article
- Monoclonal Gammopathy of Neurological Significance: A Case Report and Insights on Treatment.Mediterranean journal of hematology and infectious diseases · 2025Article
- Neurological manifestations of MGUS.Hematology. American Society of Hematology. Education Program · 2024Review
- Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.Cancer medicine · 2024Article
- Clinical significance of FLC tests in patients without other evidence of hematologic disorder.Clinical and experimental medicine · 2024Article
- Article
- When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.Cancer reports (Hoboken, N.J.) · 2024Article
- Monoclonal gammopathy of increasing significance: time to screen?Haematologica · 2023Review
- Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.European journal of neurology · 2022Article
- Review
- Clinicopathologic characteristics and prognostic analysis of monoclonal gammopathy of renal significance (MGRS) in patients with IgM monoclonal gammopathy: a case series.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the benign nature of monoclonal gammopathy of undetermined significance (MGUS), mounting data are associating MGUS with the development of organ dysfunction, specifically monoclonal gammopathy of renal significance (MGRS) and monoclonal gammopathy of neurological significance (MGNS), which could be associated with substantial morbidity. Emerging evidence suggests that patients with MGRS and MGNS could benefit from treatments used for myeloma, Waldenström macroglobulinemia, or chronic lymphocytic leukemia, depending on the underlying pathology. However, the treatment of MGRS and MGNS is not standardized, and potentially effective therapies might not be reimbursed because these conditions do not formally meet the criteria for malignant processes. The present review aims at establishing standards for the evaluation and management of MGRS and MGNS, which can facilitate the diagnosis of and provide therapeutic options for treating practitioners and patients affected by these conditions. The careful design and execution of clinical trials for patients with MGRS and MGNS are positively encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.